Tag : BREAST CANCER

Analysis of the SEER-MHOS database found that vaginal estrogen use was associated with reduced overall mortality in hormone receptor–positive (HR+) breast cancer patients, without increasing breast cancer–specific mortality. These findings may help inform discussions on the use of vaginal estrogen in patients receiving anti-hormonal treatment.

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent subtype of the disease, accounting for approximately 70% of all cases. While first-line endocrine-based regimens demonstrate considerable efficacy, later-line single-agent chemotherapy has limited effectiveness, highlighting a significant unmet need.